Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sapanisertib - Takeda Oncology

Drug Profile

Sapanisertib - Takeda Oncology

Alternative Names: CB-228; HY-13328; INK-128; MLN-0128; TAK-228

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellikine
  • Developer Calithera Biosciences; Dana-Farber Cancer Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); M. D. Anderson Cancer Center; National Cancer Institute (USA); Stanford University School of Medicine; Takeda; Takeda Oncology
  • Class Antineoplastics; Benzoxazoles; Pyrazolones; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Endometrial cancer; Fallopian tube cancer; Glioblastoma; Neuroendocrine tumours; Ovarian cancer; Peritoneal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Soft tissue sarcoma; Thyroid cancer; Urogenital cancer
  • Phase I/II Liver cancer; Merkel cell carcinoma; Sarcoma
  • Preclinical Leukaemia
  • No development reported Cancer; Non-small cell lung cancer; Solid tumours
  • Discontinued HER2 negative breast cancer; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Triple negative breast cancer; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 08 Sep 2023 National Cancer Institute suspends a phase I trial for non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (PO) due to drug supply issues (NCT04250545)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top